Clinical trials.

RVS of CNY participates in industry-sponsored and investigator-initiated clinical trials in retinal disease. Below are our currently enrolling and upcoming studies. To inquire about eligibility, ask your referring physician or contact our research coordinator. We keep this page as up to date as possible, but trial status can change quickly — please call to confirm before referring or planning a visit.

Currently enrolling

Updated as frequently as possible

TRL-01

MalbecWet AMD

MK-8748, an investigational bispecific Tie2 activator and VEGF inhibitor, versus standard Eylea injections for wet AMD. Roughly two-year study.

Enrolling

TRL-02

ABP938Wet AMD · Treatment-Naïve

ABP938, an investigational aflibercept 8 mg biosimilar, versus Eylea HD in treatment-naïve wet AMD. One-year study.

Enrolling

TRL-03

SiennaGeographic Atrophy

Subcutaneous pozelimab plus cemdisiran versus cemdisiran alone versus placebo for geographic atrophy secondary to AMD. Two-year study.

Enrolling

TRL-04

Galaxy ONLGeographic Atrophy · Non-Subfoveal

ONL 1204 versus Izervay versus sham for non-subfoveal geographic atrophy. 72-week study.

Enrolling

TRL-05

Astellas Real-WorldGeographic Atrophy · Izervay

Real-world observational study of Izervay (avacincaptad pegol) for geographic atrophy. Five-year study.

Enrolling

TRL-06

Sanofi SAR446597Geographic Atrophy · Non-Subfoveal · Gene Therapy

SAR446597, an investigational one-time gene therapy injection designed to block two parts of the complement pathway, versus sham for non-subfoveal geographic atrophy secondary to AMD. One-year study with long-term follow-up.

Enrolling

TRL-07

4SightDiabetic Macular Edema · Treatment-Naïve · Gene Therapy

4D-150, an investigational one-time gene therapy injection, versus ongoing Eylea injections for treatment-naïve diabetic macular edema. All participants receive four Eylea loading doses before randomization. Two-year study.

Enrolling

TRL-08

SyrahDiabetic Macular Edema

MK-8748, an investigational bispecific Tie2 activator and VEGF inhibitor, at two dose levels versus standard Eylea injections for diabetic macular edema. Treatment-naïve and previously treated patients eligible. Two-year study.

Enrolling

Upcoming

We are also planning future trials in geographic atrophy, wet AMD, and retinal vein occlusion, with new studies expected to open over the coming months.

How to inquire about a trial

If you are a patient, the best path is to ask your referring eye doctor whether enrollment may be appropriate, or to bring it up at your next visit with us. If you are a physician interested in referring for a specific trial, please contact our research coordinator at (315) 445-8166.

Regulatory & oversight

Institutional Biosafety Committee oversight: Advarra IBC meeting minutes (PDF).